secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001104659-22-077920
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia appoints Drs. Strahlman and Palanki as independent directors, board expands to 8 seats
--------------------------------------------------------------------------------

- Both appointments effective July 1, 2022; board increases from 6 to 8 members.
- Dr. Strahlman, former EVP R&D at BD and ex-CMO at GSK, joins audit and compensation committees.
- Dr. Palanki, EVP Commercial Strategy at REGENXBIO with Santen/Genentech background, joins compensation committee.
- Both directors determined independent under SEC and Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465922077920/0001104659-22-077920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465922077920/tm2220584d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-077920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer